Ixekizumab治疗未用过生物制剂的银屑病关节炎患者:III期临床试验SPIRIT-P1的3年结果
SPIRIT-P1是一项III期研究,未用过生物制剂的PsA患者随机接受安慰剂、阿达木单抗或ixekizumab(每2周或每4周),第24周后安慰剂和阿达木单抗组重随机至ixekizumab。156周时IXEQ2W和IXEQ4W的ACR20应答率分别为62.5%和69.8%,安全性与既往报告一致,影像学进展抑制持续。
要点
- IXEQ2W和IXEQ4W的ACR20应答率在第156周分别为62.5%和69.8%。
- 不良事件发生率IXEQ2W为38.0,IXEQ4W为38.1;严重不良事件分别为5.2和8.0。
- 影像学进展抑制持续至第156周,IXEQ2W为61%,IXEQ4W为71%。
核心结论
- 在156周的ixekizumab治疗中,安全性特征与既往报告一致,PsA体征和症状持续改善,包括影像学进展率持续较低。
研究设计与样本
- III期研究,未用过生物制剂的PsA患者随机接受安慰剂、阿达木单抗40 mg每2周、ixekizumab 80 mg每2周或每4周(初始160 mg)。
- 第24周(应答不足者第16周)后,阿达木单抗(经8周洗脱)和安慰剂患者重随机至IXEQ2W或IXEQ4W。
- 417例患者中381例进入延伸期,381例中243例(63.8%)完成156周研究。
主要发现
- IXEQ2W(n=189)的治疗中出现的不良事件和严重不良事件发生率分别为38.0和5.2;IXEQ4W(n=197)分别为38.1和8.0。
- IXEQ4W组发生1例死亡。
- IXEQ2W和IXEQ4W的ACR20应答率持续至第156周分别为62.5%和69.8%,ACR50为56.1%和51.8%,ACR70为43.8%和33.4%。
- IXEQ2W和IXEQ4W的PASI 75分别为69.1%和63.5%,PASI 90为64.5%和51.2%,PASI 100为60.5%和43.6%。
- 影像学进展抑制持续至第156周,IXEQ2W为61%,IXEQ4W为71%。
关键数值与推荐
- ACR20应答率:IXEQ2W 62.5%,IXEQ4W 69.8%(第156周)。
- ACR50应答率:IXEQ2W 56.1%,IXEQ4W 51.8%;ACR70应答率:IXEQ2W 43.8%,IXEQ4W 33.4%。
- PASI 75:IXEQ2W 69.1%,IXEQ4W 63.5%;PASI 90:IXEQ2W 64.5%,IXEQ4W 51.2%;PASI 100:IXEQ2W 60.5%,IXEQ4W 43.6%。
- 影像学进展抑制:IXEQ2W 61%,IXEQ4W 71%。
临床怎么用
- 对于未用过生物制剂的活动性PsA患者,ixekizumab 80 mg每2周或每4周治疗至156周可维持ACR和PASI应答。
- 长期治疗中需关注不良事件,严重不良事件发生率IXEQ2W为5.2、IXEQ4W为8.0。
局限性
- 延伸期采用改良无应答者填补法,影像学进展采用线性外推(改良总Sharp评分=0)。
- 156周完成率63.8%,存在脱落。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. METHODS: In a phase III study, patients naïve to biologic treatment were randomized to placebo, adalimumab 40 mg every 2 weeks (ADA; active reference) or ixekizumab 80 mg every 2 weeks (IXEQ2W) or every 4 weeks (IXEQ4W) after an initial dose of 160 mg. At week 24 (week 16 for inadequate responders), ADA (after 8-week washout) and placebo patients were re-randomized to IXEQ2W or IXEQ4W. Outcomes were evaluated using a modified non-responder imputation [linear extrapolation for radiographic progression (modified total Sharp score = 0)] during extended treatment until week 156. RESULTS: Of 417 patients, 381 entered the extension, and 243 of 381 (63.8%) completed the 156-week study. Incidence rates of treatment-emergent and serious adverse events, respectively, were 38.0 and 5.2 with IXEQ2W (n = 189) and 38.1 and 8.0 with IXEQ4W (n = 197). One death occurred (IXEQ4W). With IXEQ2W and IXEQ4W, respectively, the response rates persisted to week 156 as measured by the ACR response ≥20% (62.5 and 69.8%), ≥50% (56.1 and 51.8%) and ≥70% (43.8 and 33.4%), psoriasis area and severity index (PASI) 75 (69.1 and 63.5%), PASI 90 (64.5 and 51.2%) and PASI 100 (60.5 and 43.6%). Inhibition of radiographic progression also persisted to week 156 in 61% of IXEQ2W and 71% of IXEQ4W patients. CONCLUSION: In this 156-week study of ixekizumab, the safety profile remained consistent with previous reports, and improvements in signs and symptoms of PsA were observed, including persistent low rates of radiographic progression. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01695239, EudraCT 2011-002326-49.
引用
- Chandran V, van der Heijde D, Fleischmann RM, et al. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020. PMID: 32031665. doi:10.1093/rheumatology/kez684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。